Burden of Chronic spontaneous urticaria
6 evidence topics · 22 sources
Summary: definition and classification
The international guideline defines chronic urticaria (CU) as wheals, angioedema, or both occurring for more than 6 weeks, and classifies chronic spontaneous urticaria (CSU) as the form with no definite eliciting factor. CSU was previously known as chronic idiopathic urticaria. The draft AAAAI/ACAAI Joint Task Force guideline states that “60% of CU have CSU alone”. The international guideline attributes the signs and symptoms to activation of skin mast cells and the release of their mediators, and states that in more than 50% of patients with CSU the pathophysiology is driven by type I (autoallergy) and type IIb autoimmune mechanisms.
Summary: United States prevalence and incidence
US estimates depend on the population counted and the case definition:
- Chronic urticaria, point prevalence: 0.1% (95% CI 0.1 to 0.1) in Northern American studies in a meta-analysis of population-based studies, compared with 0.5% in Europe and 1.4% in Asia.
- Chronic urticaria, adults in electronic health records: 0.23%, or 230 cases per 100,000 adults, in a cross-sectional analysis of more than 55 million people; the authors estimate that more than 500,000 people in the United States have CU. Adjusted prevalence was 310 per 100,000 in women and 146 per 100,000 in men.
- Diagnosed CSU (2 or more ICD-9 or ICD-10 codes recorded at least 6 weeks apart), period prevalence in three US databases from 2012 to 2018 (MarketScan to 2017): 0.120% to 0.277% among adults and 0.193% to 0.304% among pediatric patients. Annual adult prevalence rose from 0.052% in 2012 to 0.191% in 2018, and adult incidence ranged from 0.039 to 0.102 per 100 person-years. This study was funded by Novartis.
- Diagnosed CSU, cumulative prevalence in adults in HealthVerity claims from 2017 to 2022: 0.57% (women 0.80%; men 0.32%), with an average annual incidence of 0.08%. At least one author is affiliated with US Medical Affairs, Novartis Pharmaceuticals Corp.
- Self-reported CSU diagnosed by a healthcare provider in the past 12 months, adults in the 2019 National Health and Wellness Survey: weighted prevalence 0.78% (95% CI 0.78% to 0.78%); 635 of 74,994 respondents reported CSU. This study was funded by Novartis.
In the international CURE registry, 2994 of 4136 participants with CSU (72.4%) were female.
Summary: natural history, duration, and mortality
- Course: the international guideline states that CU can have daily or almost daily signs and symptoms or an intermittent or recurrent course, that CSU episodes may recur after months or years of full remission, and that concomitant chronic inducible urticaria, high disease activity, elevated CRP, or angioedema indicate a prolonged duration and suboptimal response to antihistamines.
- Remission: a targeted literature review of 10 publications estimated cumulative weighted average remission of 17% at year 1, 45% at year 5, and 73% at year 20, and states that the average disease duration in CSU has been estimated to be 5 years. In an electronic health record cohort of 112,443 adults with CU, median time to clinical remission ranged from 4.1 months (cluster 1, 32.6% of participants, relapse rate 38.0%) to 33.8 and 44.6 months (clusters 3 and 4, 21.4% and 19.4% of participants, relapse rates 75%).
- Duration in the United States: mean (SD) disease duration was 11.0 (12.6) years among survey respondents with physician-diagnosed CSU.
- Mortality: in a TriNetX cohort of 264,680 propensity score-matched adults with CSU and the same number of controls, all-cause mortality hazard ratios were 2.10 at 3 months, 1.77 at 1 year, and 1.69 at 5 years. The authors state that no causal inferences can be drawn because the database cannot identify the cause of death.
Summary: clinical presentation and comorbidities
- Presentation: wheals are circumscribed superficial swellings with reflex erythema and itch or burning that resolve within 30 minutes to 24 hours; angioedema is a deeper swelling with tingling, burning, tightness, or pain that can take up to 72 hours to resolve.
- Angioedema: among 673 adults with inadequately controlled CSU, medical records documented CSU-associated angioedema in 58.5% (394 of 673), and 65.8% (427 of 649) reported angioedema in the previous 12 months. Among US survey respondents with physician-diagnosed CSU, 49.1% reported angioedema in the past 3 months.
- Comorbidities: the international guideline names chronic inducible urticaria, autoimmune diseases, metabolic syndrome, and allergies as the most common comorbidities, and depression, anxiety, sexual dysfunction, and sleep disturbance as common consequences. Most studies report IgG antithyroid autoantibodies in 10% or more of patients with CSU. In a meta-analysis of participants with chronic urticaria, 56,258 of 177,998 (31.61%) had a psychiatric comorbidity, compared with 4.6% of controls.
- US claims: among 224,958 adults with CSU, the proportion with claims for mental health conditions rose from 40.6% at baseline to 56.3% during follow-up, and for sleep-related conditions from 8.8% to 15.4%. In the TriNetX electronic health record cohort, compared with controls, adults with CSU had hazard ratios of 3.14 for suicidal ideations or suicide attempts and 2.09 for malignant neoplasms.
Summary: humanistic burden
- In 673 adults whose CSU persisted for 12 months or more despite treatment, mean (SD) Dermatology Life Quality Index (DLQI) was 9.1 (6.62), more than 40% had a DLQI of 10 or greater, and productivity impairment was 27%. This study was funded by Novartis.
- Among US adults with self-reported physician-diagnosed CSU in the 2019 National Health and Wellness Survey, mean (SD) SF-6D and EQ-5D utilities were 0.54 (0.14) and 0.62 (0.34), mean DLQI was 13.8 (11.2), 54.2% had a DLQI above 10, more than 74.0% reported anxiety (GAD-7 of 5 or more) and depression (PHQ-9 of 5 or more), and mean overall work impairment was 73.1%. This study was funded by Novartis.
- In another analysis of the 2019 US National Health and Wellness Survey, mean mental and physical component summary scores were 41.3 and 42.1 with CSU, 44.8 and 47.8 with atopic dermatitis, and 45.3 and 47.7 with psoriasis (all p < 0.001).
- In a multinational online survey of 582 participants with CSU, 84% of those taking antihistamines were inadequately controlled (UCT score below 12), and participants reported a mean diagnostic delay of 2 years.
Summary: economic burden
- In a commercially insured US population (research paid for by Genentech), CSU prevalence was 0.11%; mean all-cause healthcare costs were US$9142 per year (SD US$21,835; median US$3659) and mean urticaria-related costs were US$997; oral corticosteroids were used by 54.7% and participants had a mean of 15.1 office visits per year.
- In US HealthVerity claims, more than 50% of patients prescribed treatment had uncontrolled CSU, which was associated with increased healthcare resource use and costs.
- In the international ASSURE-CSU study, annual direct costs per patient ranged from PPP$907.1 in Italy to PPP$2984.2 in France, out-of-pocket expenses averaged nearly PPP$500 per year, 14.4% of participants had at least one CSU-related emergency department visit in the past 12 months, and 8.2% had a recorded hospitalization for CSU.
- In 2024 Oregon all-payer claims, 901 enrollees had 8,833 Xolair claims, with approximately $19.5 million in total gross payer spending and approximately $21,618 in annual gross payer spending per enrollee.
- In children younger than 12 years, CIU/CSU was associated with higher per patient per year costs than matched controls: a mean cost difference of $1853 among Medicaid enrollees and $2090 among commercially insured children.